title: Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
abstract: Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent ovarian cancer. For patients with platinum-resistant disease, single agent chemotherapy (pegylated liposomal doxorubicin, topotecan, gemcitabine or weekly paclitaxel) is the standard of care. For patients with platinum-sensitive disease, combination chemotherapy (carboplatin plus paclitaxel, pegylated liposomal doxorubicin or gemcitabine) is the standard of care. In addition, antiangiogenic therapy using bevacizumab is an established option. Future directions could include 'lines of therapy' with biologic agents driven by specific biologic targets. Data from antiangiogenic agents (trebananib, pazopanib and cediranib), antifolate drugs (farletuzumab and vintafolide), poly(ADP-ribose) polymerase inhibitors (olaparib and veliparib), mTOR inhibitors (everolimus and temsirolimus) and immune editing agents (nivolumab) have been summarized in this review.
authors.affiliation: Division of Medical Oncology, Hyogo Cancer Center, Akashi kojmatsu@hp.pref.hyogo.jp.
authors.forename: Koji
authors.initials: K
authors.lastname: Matsumoto
authors.affiliation: Division of Gynecology and Obstetrics, Kitasato University, Sagamihara.
authors.forename: Takashi
authors.initials: T
authors.lastname: Onda
authors.affiliation: Division of Gynecology and Obstetrics, Tohoku University, Sendai, Japan.
authors.forename: Nobuo
authors.initials: N
authors.lastname: Yaegashi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage; D016190:Carboplatin / Q000008:administration & dosage; D000077216:Carcinoma, Ovarian Epithelial; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068338:Everolimus; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D007191:Indazoles; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D000077594:Nivolumab; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D010793:Phthalazines / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D013449:Sulfonamides / Q000008:administration & dosage; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D019772:Topotecan / Q000008:administration & dosage; D014748:Vinca Alkaloids / Q000008:administration & dosage; D000093542:Gemcitabine; D007211:Indoles
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D016190:Carboplatin; D003841:Deoxycytidine; D004317:Doxorubicin; D000068338:Everolimus; D005492:Folic Acid; D007191:Indazoles; D000077594:Nivolumab; D017239:Paclitaxel; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011092:Polyethylene Glycols; D011743:Pyrimidines; D011799:Quinazolines; D011993:Recombinant Fusion Proteins; D020123:Sirolimus; D013449:Sulfonamides; D058570:TOR Serine-Threonine Kinases; D019772:Topotecan; D014748:Vinca Alkaloids; D000093542:Gemcitabine; C520389:EC145; C506643:liposomal doxorubicin; C521013:veliparib; C527484:farletuzumab; C401859:temsirolimus; C516667:pazopanib; C546842:MTOR protein, human; C500926:cediranib; D007211:Indoles; C531550:olaparib; C551398:trebananib
keywords: chemo-gynecology; gynecol-med; molecular Dx